Gene expression profiling of ATRA-resistant NB4-MR4 subclone (R4 cell line) treated with a CHK1 inhibitor i(MK-8776).

Acute promyelocytic leukemia (APL) is a hematological disease characterized by a balanced reciprocal translocation that leads to the synthesis of the oncogenic fusion protein PML-RARα. APL is mainly managed by a differentiation therapy based on the administration of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). However, therapy resistance, differentiation syndrome, and relapses require the development of new low-toxicity therapies based on the induction of blasts differentiation. Here, we performed a high-throughput gene expression profile of the ATRA-resistant acute promyelocytic leukemia (APL) cellline (aka R4) treated with a CHK1 inhibitor or DMSO as control. We performed a whole mRNA transcriptome analysis by Affymetrix microarray of R4 cells treated with MK-8776 (4 μM) for 96 h or DMSO as control. Two biological replicates were performed for each condition.